NLTBF yields 2.41% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, NLTBF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NLTBF + JNJ for your $10,000?
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products for medical technology, pharmaceutical, consumer electronics, telecom, automotive, and other industrial sectors in North America, Sweden, Asia, and other Europe region. The company offers consumables and reusable labware for clinical, chemical, forensic, research, and industrial testing laboratories; manufactures pipette tips, deep-well plates, microtubes, and PCR products; assemblies and post-processing services; and products for primary pharmaceutical packaging, as well as for solids, creams, and ophthalmic and customized production solutions. It designs, develops, and produces advanced components, subsystems, and ready-packaged electronics products, such as laser applications and ceramics, fitness trackers, loudspeaker systems, thermostats, webcams, and vaporiser heating products; automotive products; EMI shielding, thermal interface materials, and silicone sealing and damping solutions; and supplies plastic components and assemblies for food processing equipment, such as coffee machines and blenders. The company was formerly known as Nordiska Latexfabriken i Torekov AB and changed its name to Nolato AB (publ) in 1982. Nolato AB (publ) was incorporated in 1938 and is headquartered in Torekov, Sweden.
Full NLTBF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.